

616.936

• • , , -
• • , , ,
2007 . 45 , 2004 1-2
- : , , ,
10
(), () -
[6, 9].
50 %
98 %
() 1 2 . 45
, 0,49-0,37 % [5, 6, 8, 9]. 1.
, falciparum. ()
1-2
[1-3].
Plasmodium - 20,0 % (9 28,8 % (12)
falciparum, , 44,4 % (20)
(,) [10, 11].) - , 40,0% (18)
(7) - , 15,5 %
[1, 3, 4]. 2 . 26

(1.2009, 9)

« »
 400 5 % 600
 3-
 : 1- (4-
) 200 - 57,6±9,6% (15),
 , 2-5- - 100 . 21,0±9,3 % (4).
 19 , 1- 19,2±7,7
 , % (5),
 : 1- - 160 - 15,7±8,3 % (3),
 , 2-5- - 80 (>0,05).
 .
 per os 0,1 .
 3 .
 .
 1- 1
 5,38±0,88 , 2- ,
 - 2,78±0,46 (<0,05).
 .
 1- .

1. specific adhesion and clinical disease in *Plasmodium falciparum*. Am J Trop Med Hyg. 1997;57:389–398.
2. // 7. Gamain B, Smith JD, Miller LH, Baruch DI. Modifications in the CD36 binding domain of the *Plasmodium falciparum* variant antigen are responsible for the inability of chondroitin sulfate A adherent parasites to bind CD36. Blood. 2001;97:3268–3274.
3. // 8. Barragan A, Kremsner PG, Wahlgren M, Carlson J. Blood group A antigen is a coreceptor in *Plasmodium falciparum* rosetting. Infect Immun. 2000;68:2971–2975.
3. // 9. Cockburn IA, Mackinnon MJ, O'Donnell A, et al. From The Cover: A human complement receptor 1 polymorphism that reduces *Plasmodium falciparum* rosetting confers protection against severe malaria. Proc Natl Acad Sci USA. 2004;101:272–277.
4. Malaria. In: Tropical Disease Research. Progress 1995 - 1996. WHO, TDR, Geneva, 1997;41-61.
5. Ockenhouse CF, Ho M, Tandon NN, et al. Molecular basis of sequestration in severe and uncomplicated *Plasmodium falciparum* malaria: Differential adhesion of infected erythrocytes to CD36 and ICAM-1. J Infect Dis. 1991;164:163–169.
6. Newbold C, Warn P, Black G, et al. Receptor-

11. Chotivanich K, Udomsangpetch R, Simpson JA, et al. Parasite multiplication potential and the severity of Falciparum malaria. *J Infect Dis.* 2000;181:1206–1209.

612.825.8-613,685

2001-2007

(29-35).

[1-8].

[9-11].

(1.2009, 9)